To establish a physiologically based pharmacokinetic (PBPK) model of imipenem, predict its exposure in pediatric patients with different renal function, and optimize the dosing regimen.
A Drug–Microbiome–Drug Interaction Impacts Co-Prescribed Medications for Parkinson’s Disease
Simultaneous prescription of multiple drugs is widespread in medicine. Although the gut microbiome is implicated in drug responses, its role in mediating drug–drug interactions is unexplored
Nanoformulation Enabling Repurposing of Niclosamide for the Treatment of Pancreatic Cancer: Rapidly Soluble Oral Formulation for Enhanced Bioavailability
Pancreatic ductal adenocarcinoma (PDAC) is relatively uncommon yet remains one of the most lethal cancers worldwide.
Nonlinear Mixed-Effects Modeling to Characterize the Pharmacokinetics of a Novel Mithramycin Analogue for Ewing Sarcoma in Mice
To develop a pharmacokinetic model for a novel mithramycin analogue, MTMSA-Trp, in mice and characterize dose-dependent disposition to support future pharmacokinetic-pharmacodynamic (PK/PD) and exposure-e cacy analyses.
Piperazine-Thiourea Hybrids as Novel Antiplatelet Agents Targeting COX-1: Synthesis, in Vitro, and in Silico Evaluation
Cardiovascular diseases (CVDs) remain the leading cause of mortality worldwide, reinforcing the need for safer and more effective antiplatelet therapies.
Pharmacokinetic Evaluation of Etoricoxib 120mg Tablets in Healthy Human Pakistani Volunteers: In-Vivo In-Silico Bridging for Bioequivalence
Etoricoxib is a selective cyclooxygenase-2 inhibitor widely used for the treatment of pain and inflammatory conditions.
In Silico Designing of Palbociclib Loaded Plga Long-Acting Intramuscular Injection for Palliative Therapy of HR+/HER2− Metastatic Breast Cancer
Palbociclib (PBB) is an oral cyclin-dependent kinase 4/6 (CDK4/6) inhibitor approved for the treatment of HR+/HER2− breast cancer.
Comparison of Population Pharmacokinetic Platforms, Monolix and Phoenix for Cephalexin in Infants
Cephalexin is a commonly used antibiotic for pediatric populations, however, data to guide effective oral dosing in young infants are limited.
Population Pharmacokinetics of Encorafenib and Binimetinib in Real-World Patients with BRAFV600E/K-Mutant Metastatic Melanoma
Encorafenib and binimetinib pharmacokinetic (PK) studies in real-world cancer patients remain scarce.
Integrating Systemic Toxicity and Toxicokinetic Data to Inform the Need for Subchronic Dog Studies in Human Health Safety Assessments of Agrochemicals
Regulatory testing for agrochemicals has traditionally included a 90-day toxicity study in a non-rodent species, usually the dog.
A Phase 1 Evaluation of Inhaled Oxytocin: Physiologically-Based Pharmacokinetic Model Informed Dosing of a Novelheat-Stable Oxytocin Delivery System
To develop and validate a physiologically-based pharmacokinetic (PBPK) modelenabling inhaled oxytocin dose selection for clinical evaluation.
Prediction of the Lurasidone–Posaconazole Drug–Drug Interaction Using Physiologically Based Pharmacokinetic Modeling
Lurasidone is an atypical antipsychotic drug that metabolized by cytochrome P4503A4 (CYP3A4). Posaconazole is a triazole antifungal agent known to inhibit CYP3A4activity.
Metabolic Profiling and Detoxification of Eupalinolide A and B in Human Liver Microsomal Systems
Eupalinolide A (EA, Z-configuration) and Eupalinolide B (EB, E-configuration) are cis-trans isomeric sesquiterpenoid monomers isolated from Eupatorium lindleyanum DC. (Asteraceae).
Automated Concentration-QT data preparation, model selection and reporting in R
Since the publication of the ICH E14 guidance in 2015, QT interval prolongation as-sessment can be carried out with a concentration-QTc modeling approach as part of single- or mul-tiple- dose escalation studies, instead of conducting a thorough QT/QTc study.
Pharmacokinetic Studies and Synergistic Antitumor Effects of Cannabichromene and Cannabidiol in Drug-Resistant Breast Cancers
Triple-negative breast cancer (TNBC) is highly aggressive with limited treatment options, and resistance to doxorubicin (DOX) further compromises outcomes.
High-Throughput Physiologically Based Pharmacokinetic Model for Rodent Pharmacokinetics Prediction Using Machine Learning-Predicted Inputs and a Large In Vivo Pharmacokinetics Data Set
Accurate prediction of the pharmacokinetic (PK) properties of small-molecule drug candidates is a critical aspect of pharmaceutical research.
Design, Synthesis, and Pharmacological Evaluation of Metabolically Stable Apelin Receptor Antagonists with Improved In Vivo Exposure and Efficacy in Ovarian Cancer
The apelin receptor (APJ) has emerged as a potential novel therapeutic target in cancer due to its role in regulating cell proliferation, angiogenesis, and metastasis.
Investigating the SNAC-To-Drug Ratio for the Oral Absorption of Cyanocobalamin in Rats
The oral route of administration continues to be the preferred and most convenient method for drug delivery among both patients and healthcare professionals.
Novel Descriptors and Models for More Accurate ADME Predictions of Beyond Rule of Five Molecules
This study addresses the critical need for improved physicochemical descriptors and predictive models tailored to beyond Rule of Five (bRo5) compounds, including PROTACs and cyclic peptides. B
Development of a Pregnancy-Specific Physiologically Based Pharmacokinetics (PBPK) Model for Aspirin
Aspirin is one of the most commonly used medications in pregnancy, particularly for the prevention of hypertensive disorders.